Jabal Ali buying Ecstasy

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Jabal Ali buying Ecstasy

The latest news and analysis from the Emirates. Packages of illegal drugs can be clearly seen in this X-ray of a smuggler's stomach. Courtesy: Royal Oman Police. Arrest of 'mules' in Dubai sheds light on dangerous and desperate drug trade. Prosecutor accuses crime gangs that recruit smugglers of 'preying on the poor'. Salam Al Amir. Listen In English. Listen In Arabic. By signing up, I agree to The National's privacy policy.

Arrest of 'mules' in Dubai sheds light on dangerous and desperate drug trade

Jabal Ali buying Ecstasy

The pharmaceutical market in the Middle East is dominated by the western multinationals. However, several new pharmaceutical projects are coming up in these countries and companies based there have commenced negotiations with several Indian companies for collaboration and technology transfer. This trend is despite the widespread notion amongst Indian companies that the Arab world is very much biased towards the west when it comes to sourcing pharmaceuticals. Traditionally, pharmaceutical firms cherished the notion that Arabs would never allow Indian manufacturing in their land even though they would not hesitate buying drugs from those companies which enjoy global reputation. One strip of cephalosporin antibiotic cost around rupees in Indian value terms in Dubai. Whereas the same is priced 12 to 18 rupees here,' comments a mid-cap Indian drug manufacturer. But it is very difficult to penetrate this market as the regulations in these countries are very stringent, he complains. Secondly, the company should be registered atleast in two GCC countries. And the most difficult proposition is that to get an Arab partner who will hold 51 per cent in the venture,' he explains. However, things are changing for the better, of late, believes a few of the Indian entreupreners who still dared to venture in to the lucrative Arab market. The Arabs have started realizing that the Indian companies are placed amongst the best in the world of pharmaceu-tical manufacturing,' says Mukund Mehta of Kilitch Drugs India Ltd. The Mumbai based Kilitch is one of the companies which made attempts to start joint venture manufacturing in countries like UAE and Yemen. The situation that existed pre is no more now. The Arabs no more feel that the west is the only place to procure quality drugs. They are increasingly turning towards India also, according to Mehta. The Parijat Enterprises, the promoters of Kopran, is also providing technology transfer to Globalpharma. Besides manufacturing and marketing Kopran's products, Global Pharma is supposed to be involved in contract manufacturing , export and in-licensing of products. The Globalpharma site is built on a plot measuring approximately square metres in Dubai Investment Park, about 50 kms from Dubai City. The factory has two separate manufacturing units, for penicillin and non-penicillin products. The range of dosage forms manufactured at Globalpharma includes tablets, capsules,and dry syrups in the penicillin block and tablets, capsules, liquid oral syrups and suspensions in the non-penicillin block. Ranbaxy and Pfizer will provide knowledge, technology and training for the manufacturing process. In return, they will be able to use a portion of the manufacturing capacity. Ranbaxy will manufacture another five drugs at the new plant for worldwide distribution in the second phase. The plant, which covers 17, sq. Neopharma's manufacturing range includes anti-infectives, anti-inflammatory and arthritis, cardiovascular, anti-diabetic, gastrointestinal protectives, drugs for respiratory system and multivitamins. In the first phase, Neopharma targets million tablets, 45 million units of antibiotics, 30 million capsules and nine million liquid oral doses for 45 different medicines. The second phase of the Neopharma plant is expected allow production of over varieties of drugs. The antibiotics unit will conform to all international standards set up by the FDA and European authorities. Dr Reddy's Laboratories, another Indian company, has expressed a strong interest in a technical collaboration with Neopharma for some of their manufacturing processes. Dr Reddy's has also plans to carry out some formulation and finishing at the Neopharma facility after the initial active pharmaceutical ingredient API production at their FDA approved plant in India. The facility is designed to manufacture tablets, capsules and liquid dosage forms. The state-of-the-art plant, which went onstream last year, has the capacity to manufacture 25 million tablets, 10 million capsules and 0. List your company in Pharma Mart Now! Register Login. Website : Please Enter Proper Website. Please write your message. Pharma Mart Search. Please Enter Company And Vendor. Enquiry Form Please Enter Name. Please Enter Comment.

Jabal Ali buying Ecstasy